Cited by 372Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorMental Health and Psychiatry

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

5-HT2and D2Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation

Kapur, Shitij, Zipursky, Robert B., Remington, Gary, Jones, Corey, DaSilva, Jean, Wilson, Alan A., Houle, Sylvain·1998·American Journal of Psychiatry

DOI 10.1176/ajp.155.7.921

Open this paper in CoChat — free account

Abstract

OBJECTIVE: Olanzapine is a new atypical antipsychotic recently introduced for the treatment of schizophrenia. The purpose of this study was to investigate olanzapine's binding to the serotonin 5-HT2 and dopamine D2 receptors in schizophrenic patients being treated with clinically relevant doses. METHOD: Twelve patients with schizophrenia were randomly assigned to 5, 10, 15, or 20 mg/day of olanzapine in a prospective fashion. Three other subjects taking 30-40 mg/day were also included. Once steady-state plasma levels were achieved, dopamine D2 and serotonin 5-HT2 receptors were assessed by using [11C]raclopride and [18F]setoperone positron emission tomography imaging, respectively. Ratings of clinical status, extrapyramidal side effects, and prolactin levels were also obtained. RESULTS: Olanzapine induced near saturation of the 5-HT2 receptors, even at 5 mg/day. Its D2 occupancy increased with dose: patients taking 5-20 mg/day showed 43%-80% D2 occupancy, while patients taking 30-40 mg/day showed 83%-88%. CONCLUSIONS: Olanzapine is a potent 5-HT2 blocker and shows a higher 5-HT2 than D2 occupancy at all doses. However, its D2 occupancy is higher than that of clozapine and similar to that of risperidone. In the usual clinical dose range of 10-20 mg/day, its occupancy varies from 71% to 80%, and this restricted range may explain its freedom from extrapyramidal side effects and prolactin elevation. However, doses of 30 mg/day and higher are associated with more than 80% D2 occupancy and may have a higher likelihood of prolactin elevation and extrapyramidal side effects.

Integrity signals

Registry

Crossref · 10.1176/ajp.155.7.921

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,179
Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,420
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,352
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Gompel, P. V., Lesage, A. S., Loore, K. D., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P. M., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,061
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial
Tollefson, G. D., Beasley, C. M., Tran, P. V., Street, J. S., Krueger, J. A., Tamura, R., Graffeo, K. A., & Thieme, M. E. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperidol in the Treatment of Chronic Schizophrenic Patients
Chouinard, G., Jones, B., Remington, G. J., BLOOM, D., Addington, D. E., MacEwan, G. W., Labelle, A., Beauclair, L., & Arnott, W. S. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199302000-00004 · Cited by 876
Self-citation

Show all 41 references

Research works printed but not linked: 1

Janicak P, Javaid J, Sharma R, Leach A, Easton M, Dowd S, Davis J, Dowd S, Davis J: Haloperidol dose/response relationship—results from a random-assignment, double blind study (abstract). Neuropsychopharmacology 1994; 10:106S

Sorted by citations

Items 101–200 of 372

Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide’s antiproliferative effect
Karpel‐Massler, G., Kast, R. E., Westhoff, M., Dwucet, A., Welscher, N. E., Nonnenmacher, L., Hlaváč, M., Siegelin, M. D., Wirtz, C. R., Debatin, K., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1688-7 · Cited by 63
Clinical utility of drug measurement and pharmacokinetics – therapeutic drug monitoring in psychiatry
Hiemke, C. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0430-1 · Cited by 65
Olanzapine
Bhana, N., & Perry, C. M. (2001) · CNS Drugs · doi:10.2165/00023210-200115110-00005 · Cited by 62
Effects of the Atypical Antipsychotic Olanzapine on Reproductive Function and Weight Gain in Female Rats
Fell, M. J., Marshall, K. M., Williams, J., & Neill, J. C. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104042613 · Cited by 62
A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
Coppola, D., Liu, Y., Gopal, S., Remmerie, B., Samtani, M. N., Hough, D. W., Nuamah, I., Sulaiman, A., & Pandina, G. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-26 · Cited by 61
“This is within the range (60-80%) associated with antipsychotic efficacy [29-33].”
Background
Modification of spatial recognition memory and object discrimination after chronic administration of haloperidol, amitriptyline, sodium valproate or olanzapine in normal and anhedonic rats
Orsetti, M., Colella, L., Dellarole, A., Canonico, P. L., & Ghi, P. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706006705 · Cited by 62
Plasma Olanzapine in Relation to Prescribed Dose and Other Factors
Patel, M. X., Bowskill, S. V. J., Couchman, L., Lay, V., Taylor, D. M., Spencer, E. P., & Flanagan, R. J. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318221b408 · Cited by 60
Polypharmacy With Second-Generation Antipsychotics: A Review of Evidence
Pandurangi, A. K., & Dalkiliç, A. (2008) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000341890.05383.45 · Cited by 57
Depression and Impulsivity as Pathways to Violence: Implications for Antiaggressive Treatment
KRAKOWSKI, M. I., & Czobor, P. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt117 · Cited by 58
Risk of osteoporosis and fracture incidence in patients on antipsychotic medication
Graham, S. M., Howgate, D. J., Anderson, W. C., Howes, C., Heliotis, M., Mantalaris, A., Tsiridis, E. E., & Tsapakis, E.-M. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.560112 · Cited by 57
Neuroreceptor imaging in psychiatric disorders
Frankle, W. G., & Laruelle, M. A. (2002) · Annals of Nuclear Medicine · doi:10.1007/bf02988639 · Cited by 58
In Silico Receptorome Screening of Antipsychotic Drugs
Vidal, D., & Mestres, J. (2010) · Molecular Informatics · doi:10.1002/minf.201000055 · Cited by 58
Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications
Frankle, W., Gil, R. B., Hackett, E., Mawlawi, O., Zea-Ponce, Y., Zhu, Z., Kochan, L., Cangiano, C., Slifstein, M., Gorman, J., et al. (2003) · Psychopharmacology · doi:10.1007/s00213-004-1852-4 · Cited by 50
Atypical antipsychotics and mood stabilization in bipolar disorder
Brambilla, P., Barale, F., & Soares, J. C. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1322-9 · Cited by 55
Subcutaneous Olanzapine for Hyperactive or Mixed Delirium in Patients with Advanced Cancer: A Preliminary Study
Elsayem, A. F., Bush, S. H., Munsell, M. F., Curry, E. A., Calderon, B. B., Paraskevopoulos, T., Fadul, N. A., & Bruera, E. D. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2010.02.017 · Cited by 54
Antipsychotics, dopamine D₂ receptor occupancy and clinical improvement in schizophrenia: a meta-analysis
Yilmaz, Z., Zai, C. C., Hwang, R., Mann, S., Arenovich, T., Remington, G., & Daskalakis, Z. J. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.06.027 · Cited by 52
Self-citation
Receptor targets for antidepressant therapy in bipolar disorder: An overview
Fountoulakis, K. Ν., Kelsoe, J. R., & Akiskal, H. S. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.04.043 · Cited by 52
Does olanzapine inhibit the psychomimetic effects of Δ 9 -tetrahydrocannabinol?
Kleinloog, D., Liem-Moolenaar, M., Jacobs, G. E., Klaassen, E. S., de Kam, M., Hijman, R., & van Gerven, J. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112446534 · Cited by 52
Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol
Markianos, M., Hatzimanolis, J., & Lykouras, L. P. (2001) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060170049 · Cited by 52
Pharmacogenetics of Olanzapine Metabolism
Söderberg, M. M., & Dahl, M. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.120 · Cited by 50
Effect of antipsychotics on cortical inhibition using transcranial magnetic stimulation
Daskalakis, Z. J., Christensen, B. K., Chen, R. E., Fitzgerald, P. B., Zipursky, R. B., & Kapur, S. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1548-1 · Cited by 51
Self-citation
The Dopamine Hypothesis of Schizophrenia
Gründer, G., & Cumming, P. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801829-3.00015-x · Cited by 57
Striatal and Extrastriatal D2/D3-Receptor-Binding Properties of Ziprasidone
Vernaleken, I., Fellows, C., Janouschek, H., Bröcheler, A., Veselinović, T., Landvogt, C., Boy, C., Buchholz, H., Spreckelmeyer, K. N., Bartenstein, P., et al. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818ba2f6 · Cited by 48
How do the atypical antipsychotics work?
Ananth, J., Burgoyne, K. S., Gadasalli, R., & AQUINO, S. (2001) · PubMed Central · Cited by 48
Role of Neuroactive Steroid Allopregnanolone in Antipsychotic-like Action of Olanzapine in Rodents
Ugale, R. R., Hirani, K., Morelli, M., & Chopde, C. T. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300460 · Cited by 48
Olanzapine-Induced Tardive Dystonia
Dunayevich, E., & Strakowski, S. M. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.10.1662 · Cited by 47
Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects
Coccurello, R., Caprioli, A., Ghirardi, O., Conti, R., Ciani, B., Daniele, S., Bartolomucci, A., & Moles, A. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0368-5 · Cited by 47
Comparison Between Olanzapine and Haloperidol on Procedural Learning and the Relationship With Striatal D2 Receptor Occupancy in Schizophrenia
Paquet, F., Soucy, J., Stip, É., Lévesque, M., Elie, A., & Bédard, M. (2004) · Journal of Neuropsychiatry · doi:10.1176/jnp.16.1.47 · Cited by 46
Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?
Hiemke, C. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-1005-y · Cited by 45
Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders
Lafuente, A., Bernardo, M., Mas, S., Crescenti, A., Aparici, M., Gassó, P., Deulofeu, R., Mané, A., Catalán, R., & Carné, X. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2007.08.002 · Cited by 45
Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications
Bui, K., Earley, W. R., & Nyberg, S. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.794774 · Cited by 46
Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain?
Westerink, B. H. C. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02496-2 · Cited by 45
Atypical Antipsychotic Use in the Treatment of Psychosis in Primary Care
Leo, R. J., & Regno, P. A. D. (2000) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v02n0601 · Cited by 44
Differences Between Schizophrenic and Normal Subjects Using Network Properties from fMRI
Bae, Y., Kumarasamy, K., Ali, I. M., Korfiatis, P. D., Akkus, Z., & Erickson, B. J. (2017) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-017-0020-4 · Cited by 43
Progestins' actions in the VTA to facilitate lordosis involve dopamine-like type 1 and 2 receptors
Frye, C. A., Walf, A. A., & Sumida, K. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.04.014 · Cited by 44
In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine
Raedler, T. J. (1999) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(99)00010-4 · Cited by 44
Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
Lavalaye, J., Linszen, D., Booij, J., Reneman, L., Gersons, B., & van Royen, E. V. (1999) · Psychiatry Research · doi:10.1016/s0925-4927(99)00032-3 · Cited by 47
Olanzapine
McCormack, P. L., & Wiseman, L. R. (2004) · Drugs · doi:10.2165/00003495-200464230-00006 · Cited by 43
Cerebral D2 and 5-HT2 Receptor occupancy in Schizophrenic Patients Treated with Olanzapine Or Clozapine
Moresco, R. M., Cavallaro, R., Messa, C., Bravi, D., Gobbo, C. L., Galli, L., Lucignani, G., Colombo, C., Rizzo, G., Velonà, I., et al. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800306 · Cited by 43
Applying Neuroimaging Ligands to Study Major Depressive Disorder
Meyer, J. H. (2008) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2008.02.007 · Cited by 41
First- and second-generation antipsychotic medication and cognitive processing in schizophrenia
Weickert, T. W., & Goldberg, T. E. (2005) · Current Psychiatry Reports · doi:10.1007/s11920-005-0085-5 · Cited by 41
Quetiapine Is Not Associated with Increase in Prolactin Secretion in Contrast to Haloperidol
Atmaca, M., Kuloğlu, M., Tezcan, E., Canatan, H., & Geçici, Ö. (2002) · Archives of Medical Research · doi:10.1016/s0188-4409(02)00403-4 · Cited by 41
A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy
Eugene, A. R., & Masiak, J. (2017) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2017.1314011 · Cited by 39
Serotonin and Schizophrenia
Quednow, B. B., Geyer, M. A., & Halberstadt, A. L. (2010) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(10)70102-8 · Cited by 40
Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics
Hart, X. M., Gründer, G., Ansermot, N., Conca, A., Corruble, E., Crettol, S., Cumming, P. D., Frajerman, A., Hefner, G., Howes, O. D., et al. (2024) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2024.2366235 · Cited by 39
Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors
Tadori, Y., Forbes, R. A., McQuade, R. D., & Kikuchi, T. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.02.007 · Cited by 39
Olanzapine’s effects to reduce fear and anxiety and enhance social interactions coincide with increased progestin concentrations of ovariectomized rats
Frye, C. A., & Seliga, A. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00049-5 · Cited by 36
Olanzapine-Associated Hypothermia
Blass, D. M., & Chuen, M. (2004) · Psychosomatics · doi:10.1176/appi.psy.45.2.135 · Cited by 38
D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study
Meisenzahl, E. M., Dresel, S. H. J., Frodl, T., Schmitt, G., Preuss, U. W., Rossmüller, B., Tatsch, K., Mager, T., Hahn, K. M., & Möller, H. ‐. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400405 · Cited by 38
Mood stabilizers for patients with bipolar disorder: the state of the art
Altamura, A. C., Lietti, L., Dobrea, C., Benatti, B., Arici, C., & Dell’Osso, B. M. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.181 · Cited by 39
Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET
Catafau, A. M., Suárez‐Piñera, M., Bullich, S., Llop, J., Nucci, G., Gunn, R. N., Brittain, C. F., & Laruelle, M. A. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.02.005 · Cited by 36
Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats
Fell, M. J., Neill, J. C., Rao, C., & Marshall, K. M. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0131-3 · Cited by 36
An automated blood sampler for simultaneous sampling of systemic blood and brain microdialysates for drug absorption, distribution, metabolism, and elimination studies
Gunaratna, P. C., Kissinger, P. T., Kissinger, C. B., & Gitzen, J. F. (2003) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(03)00058-3 · Cited by 35
The Pharmacological Role and Clinical Applications of Antipsychotics’ Active Metabolites: Paliperidone versus Risperidone
Álamo, C. (2013) · Clinical and Experimental Pharmacology · doi:10.4172/2161-1459.1000117 · Cited by 35
Atypical Antipsychotics: Mechanism of Action
Seeman, P. M. (2004) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.2.1.48 · Cited by 35
Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [123I]IBZM SPECT study
Bernardo, M., Parellada, E., Lomeña, F., Catafau, A. M., Font, M., Gómez, J. C., López-Carrero, C., Gutiérrez, F., Pavı́a, J., & Salamero, M. (2001) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(01)00085-3 · Cited by 35
Elevated neuronal nitric oxide synthase expression in chronic haloperidol-treated rats
Lau, Y. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00314-9 · Cited by 35
Modeling of Brain D2 Receptor Occupancy-Plasma Concentration Relationships with a Novel Antipsychotic, YKP1358, Using Serial PET Scans in Healthy Volunteers
Lim, K. S., Kwon, J. S., Jang, I.-J., Jeong, J. M., Lee, J. S., Kim, H. W., Kang, W. J., Kim, J.-R., Cho, J.-Y., Kim, E., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100049 · Cited by 34
Can olanzapine be implicated in causing serotonin syndrome?
HASLETT, C. D., & Kumar, S. (2002) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2002.01050.x · Cited by 34
Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
Cunningham, J. I., Eyerman, D. J., Todtenkopf, M. S., Dean, R. L., Deaver, D. R., Sánchez, C., & Namchuk, M. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119856850 · Cited by 33
Olanzapine Sensitization and Clozapine Tolerance: From Adolescence to Adulthood in the Conditioned Avoidance Response Model
Qiao, J., Li, H., & Li, M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.213 · Cited by 32
Blinded Prospective Evaluation of Computer-Based Mechanistic Schizophrenia Disease Model for Predicting Drug Response
Geerts, H., Spiros, Ä., Roberts, P., Twyman, R. E., Alphs, L. D., & Grace, A. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049732 · Cited by 32
Positron emission tomography and single photon emission CT molecular imaging in schizophrenia
Erritzøe, D., Talbot, P. S., Frankle, W. G., & Abi‐Dargham, A. (2003) · Neuroimaging Clinics of North America · doi:10.1016/s1052-5149(03)00089-3 · Cited by 31
Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients
Catafau, A., Penengo, M. M., Nucci, G., Bullich, S., Corripio, I., Parellada, E., García-Ribera, C., Goméni, R., & Merlo‐Pich, E. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107083810 · Cited by 31
Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
Lorenzo, R. D. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5463 · Cited by 30
Can lipid nanoparticles improve intestinal absorption?
Mendes, M., Soares, H. T., Arnaut, L. G., Sousa, J., Pais, A. A. C. C., & Vitorino, C. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.09.065 · Cited by 30
Treatment Response to Olanzapine and Haloperidol and its Association with Dopamine D 2 Receptor Occupancy in First-Episode Psychosis
Zipursky, R. B., Christensen, B. K., Daskalakis, Z. J., Epstein, I., Roy, P., Furimsky, I., Sanger, T. M., & Kapur, S. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505000806 · Cited by 30
Self-citation
Iatrogenic Disorders Associated With Conventional vs. Atypical Antipsychotics
Nasrallah, H. A., & Mulvihill, T. (2001) · Annals of Clinical Psychiatry · doi:10.1023/a:1014629402131 · Cited by 30
Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine
Schmitt, G., Meisenzahl, E., Dresel, S. H. J., Tatsch, K., Rossmüller, B., Frodl, T., Preuss, U. W., Hahn, K. M., & Möller, H. ‐. (2002) · Journal of Psychopharmacology · doi:10.1177/026988110201600302 · Cited by 30
High-Dose Olanzapine for Treatment-Refractory Schizophrenia
Lerner, V. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200303000-00003 · Cited by 29
Antipsychotic drugs reverse the AMPA receptor‐stimulated release of 5‐HT in the medial prefrontal cortex
Amargós‐Bosch, M., Adell, A., & Artigas, F. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04532.x · Cited by 29
Classification of Neuropsychiatric Medications by Principal Mechanism of Action: A Meaningful Way to Anticipate Pharmacodynamically Mediated Drug Interactions (Part II)
Preskorn, S. (2004) · Journal of Psychiatric Practice · doi:10.1097/00131746-200405000-00006 · Cited by 29
Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications
Szmulewicz, A., Samamé, C., Caravotta, P., Martino, D. J., Igoa, A., Hidalgo-Mazzei, D., Colom, F., & Strejilevich, S. A. (2016) · International Journal of Bipolar Disorders · doi:10.1186/s40345-016-0047-3 · Cited by 28
Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions
Kolli, P., Kelley, G., Rosales, M., Faden, J., & Serdenes, R. (2023) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s391401 · Cited by 37
Aripiprazole Augmentation in Patients with Resistant Obsessive Compulsive Disorder: a Pilot Study
Chiaie, R. D., Scarciglia, P., Pasquini, M., Caredda, M., & Biondi, M. (2011) · Clinical Practice and Epidemiology in Mental Health · doi:10.2174/1745017901107010107 · Cited by 28
Conventional versus novel antipsychotics: changing concepts and clinical implications.
Remington, G. J., & Chong, S. A. (1999) · PubMed Central · Cited by 28
Self-citation
Positron emission tomography in psychiatric disorders
Newberg, A. B., Moss, A., Monti, D., & Alavi, A. A. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06162.x · Cited by 29
Multilead quantitative electroencephalogram profile and cognitive evoked potentials (P300) in healthy subjects after a single dose of olanzapine
Hubl, D., Kleinlogel, H., Fr�lich, L., Weinandi, T., Maurer, K., Holstein, W., Czekalla, J., & Dierks, T. (2001) · Psychopharmacology · doi:10.1007/s002130100861 · Cited by 27
Aripirazole—Olanzapine Combination for Treatment of Schizophrenia
Duggal, H. S. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900213 · Cited by 27
Progestin-facilitated lordosis of hamsters may involve dopamine-like type 1 receptors in the ventral tegmental area
Sumida, K., Walf, A. A., & Frye, C. A. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.02.013 · Cited by 27
Schizophrenia treatment. Critical review on the drugs and mechanisms of action of antipsychotics.
Tajima, K., Fernández, H., López-Ibor, J. L., Carrasco, J. L., & Díaz‐Marsá, M. (2009) · Actas Españolas de Psiquiatría · Cited by 26
Retracted
Allosteric Modulators of G Protein-Coupled Dopamine and Serotonin Receptors: A New Class of Atypical Antipsychotics
Fasciani, I., Petragnano, F., Aloisi, G., Marampon, F., Carli, M., Scarselli, M., Maggio, R., & Rossi, M. (2020) · Pharmaceuticals · doi:10.3390/ph13110388 · Cited by 26
Treatment-Refractory Schizophrenia in Children and Adolescents: An Update on Clozapine and Other Pharmacologic Interventions
Kranzler, H. N., Kester, H. M., Gerbino-Rosen, G., Henderson, I., Youngerman, J. K., Beauzile, G., Ditkowsky, K., & Kumra, S. (2006) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.08.008 · Cited by 26
Striatal D2 receptor occupancy in bipolar patients treated with olanzapine
Attarbaschi, T., Sacher, J., Geiss-Granadia, T., Klein, N., Mossaheb, N., Lanzenberger, R. R., Asenbaum, S., Dudczak, R., Kasper, S. F., & Tauscher, J. T. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.07.001 · Cited by 26
Therapeutic Window for Striatal Dopamine D2/3 Receptor Occupancy in Older Patients With Schizophrenia
Uchida, H., Suzuki, T., Graff‐Guerrero, A., Mulsant, B. H., Pollock, B. G., Arenovich, T., Rajji, T. K., & Mamo, D. C. (2012) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318265738f · Cited by 34
Interactions and Monitoring of Antipsychotic Drugs
Hiemke, C., & Pfuhlmann, B. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_10 · Cited by 26
Neuroreceptor Imaging Studies in Schizophrenia
Frankle, W. G. (2007) · Harvard Review of Psychiatry · doi:10.1080/10673220701679812 · Cited by 25
PET technology for drug development in psychiatry
Arakawa, R., Takano, A., & Halldin, C. (2020) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12084 · Cited by 24
Serotonin and schizophrenia
Quednow, B. B., Geyer, M. A., & Halberstadt, A. L. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00039-6 · Cited by 31
Suicidality in clozapine-treated patients with schizophrenia: Role of obsessive-compulsive symptoms
Szmulewicz, A., Smith, J. M., & Valerio, M. P. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.07.089 · Cited by 27
Haloperidol both prevents and reverses quinpirole-induced nonregulatory water intake, a putative animal model of psychogenic polydipsia
Amato, D., Stasi, M. A., Borsini, F., & Nencini, P. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1229-1 · Cited by 24
A review of olanzapine pamoate
Chue, P. S., & Chue, J. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.686169 · Cited by 24
Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: A cross-sectional study
Mizuno, Y., Bies, R. R., Remington, G. J., Mamo, D. C., Suzuki, T., Pollock, B. G., Tsuboi, T., Watanabe, K., Mimura, M., & Uchida, H. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.12.013 · Cited by 24
Self-citation
Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy
Oades, R. D., Rao, M. L., Bender, S., Sartory, G., & Müller, B. W. (2000) · Behavioural Pharmacology · doi:10.1097/00008877-200006000-00015 · Cited by 23
Adverse Effects of High-Dose Olanzapine in Treatment-Refractory Schizophrenia
Bronson, B. D., & Lindenmayer, J. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200006000-00017 · Cited by 23
Lactational exposure to atypical antipsychotic drugs disrupts the pituitary-testicular axis in mice neonates during post-natal development
Mishra, A. C., & Mohanty, B. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109348162 · Cited by 22
Molecular imaging as a guide for the treatment of central nervous system disorders
Kim, E., Howes, O. D., & Kapur, S. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.3/ekim · Cited by 22
Self-citation
Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia?
Schwenger, E. M., Dumontet, J., & Ensom, M. H. H. (2011) · Clinical Pharmacokinetics · doi:10.2165/11587240-000000000-00000 · Cited by 21
Atypical antipsychotic clozapine reversed deficit on prepulse inhibition of the acoustic startle reflex produced by microinjection of DOI into the inferior colliculus in rats
de Oliveira, R. P., Nagaishi, K. Y., & Silva, R. C. B. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.01.053 · Cited by 21
Ziprasidone for Psychotic Disorders: A Meta-Analysis and Systematic Review of the Relationship Between Pharmacokinetics, Pharmacodynamics, and Clinical Profile
Stip, É., Zhornitsky, S., Moteshafi, H., Létourneau, G., Stikarovska, I., Potvin, S., & Tourjman, V. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.10.027 · Cited by 20

Authors: Kapur, S., Zipursky, R. B., Remington, G., Jones, C., DaSilva, J., Wilson, A. A., & Houle, S.
ORCID: Kapur, Shitij
Zipursky, Robert B.
Remington, Gary
DaSilva, Jean
Houle, Sylvain
Venue: American Journal of Psychiatry
Publisher: American Psychiatric Association Publishing
Published: 1998-07-01
Volume: 155
Issue: 7
Pages: 921-928
ISSN: 0002-953X (ISSN-L)
1535-7228
DOI: 10.1176/ajp.155.7.921
OpenAlex: W2163010981
Cited by: 370
References: 41
Citations by year: 2026: 5 · 2025: 7 · 2024: 9 · 2023: 9 · 2022: 8 · 2021: 4 · 2020: 10 · 2019: 5 · 2018: 7 · 2017: 6 · 2016: 8 · 2015: 7 · 2014: 9 · 2013: 19 · 2012: 14
FWCI: 15.00
Type: journal article
Language: en
Open access: closed
Locations: American Journal of Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords: olanzapine, schizophrenia, dopamine D2 receptor occupancy, atypical antipsychotics, dose dependence, extrapyramidal symptoms, prolactin elevation, [11C]raclopride, clozapine, risperidone
MeSH terms: Olanzapine, Adult, Benzodiazepines, Carbon Radioisotopes, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Fluorine Radioisotopes, Humans, Male, Pirenzepine, Prolactin, Pyrimidinones, Receptors, Serotonin, Salicylamides, Schizophrenia, Tomography, Emission-Computed, Antipsychotic Agents, Treatment Outcome, Receptors, Dopamine D2, Raclopride

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

5-HT2and D2Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks